Zhi-Jia Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhi-Jia Sun has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Chun-Yuan Xue
Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China
1 shared publication- Lei Kang
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
1 shared publication Lu-Yuan Ma
Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China
1 shared publication- Nan Du
Department of Oncology, Chinese PLA General Hospital Fifth Medical Center, Beijing, China
1 shared publication - Nan Huo
Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China
1 shared publication Rui Cong
Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 17 August 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (9) , 1-13
STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis
Lactate dehydrogenase A (LDHA), a critical component of the glycolytic pathway, relates to the development of various cancers, including thyroid cancer. However, the regulatory mechanism of LDHA inhibition and the physiological significance of the LDHA inhibitors in papillary thyroid cancer (PTC) are unknown. Long non-coding RNA (lncRNA) plays a vital role in tumor growth and progression. Here, we identified a novel lncRNA LINC00671 negatively correlated with LDHA, downregulating LDHA expression and predicting good clinical outcome in thyroid cancer. Moreover, hypoxia inhibits LINC00671 expression and activates LDHA expression largely through transcriptional factor STAT3. STAT3/LINC00671/LDHA axis regulates thyroid cancer glycolysis, growth, and lung metastasis both in vitro and in vivo. In thyroid cancer patients, LINC00671 expression is negatively correlated with LDHA and STAT3 expression. Our work established STAT3/LINC00671/LDHA as a critical axis to regulate PTC growth and progression. Inhibition of LDHA or STAT3 or supplement of LINC00671 could be potential therapeutic strategies in thyroid cancer.
- 17 August 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (9) , 1-13
Open AccessSTAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis
Lactate dehydrogenase A (LDHA), a critical component of the glycolytic pathway, relates to the development of various cancers, including thyroid cancer. However, the regulatory mechanism of LDHA inhibition and the physiological significance of the LDHA inhibitors in papillary thyroid cancer (PTC) are unknown. Long non-coding RNA (lncRNA) plays a vital role in tumor growth and progression. Here, we identified a novel lncRNA LINC00671 negatively correlated with LDHA, downregulating LDHA expression and predicting good clinical outcome in thyroid cancer. Moreover, hypoxia inhibits LINC00671 expression and activates LDHA expression largely through transcriptional factor STAT3. STAT3/LINC00671/LDHA axis regulates thyroid cancer glycolysis, growth, and lung metastasis both in vitro and in vivo. In thyroid cancer patients, LINC00671 expression is negatively correlated with LDHA and STAT3 expression. Our work established STAT3/LINC00671/LDHA as a critical axis to regulate PTC growth and progression. Inhibition of LDHA or STAT3 or supplement of LINC00671 could be potential therapeutic strategies in thyroid cancer.